dr. pal on sequencing abiraterone and enzalutamide in mcrpc
Published 10 years ago • 234 plays • Length 0:55Download video MP4
Download video MP3
Similar videos
-
1:12
dr. pal on sequencing abiraterone and enzalutamide in mcrpc
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
1:53
dr. nicholas vogelzang discusses sequencing abiraterone and enzalutamide
-
8:12
the use of abiraterone and enzalutamide against crpc
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
25:26
psma theranostics for prostate cancer
-
18:21
decisional tools to determine need for biopsy and re-biopsy in men with elevated psas
-
9:43
transperineal biopsy & classification of risk using novel gleason pattern quantification
-
2:09
dr. charles ryan discusses abiraterone and enzalutamide for mcrpc
-
0:59
dr. crawford on abiraterone versus enzalutamide in prostate cancer
-
1:21
dr. shore on the enzalutamide mechanism of action
-
1:34
dr. chi on abiraterone versus enzalutamide for metastatic castration-resistant prostate cancer
-
2:00
dr. pal on adjuvant therapy of renal cell carcinoma
-
8:09
treating mcrpc with newer hormonal agents
-
9:42
dr. shore on therapy combination and sequencing in castration-resistant prostate cancer
-
0:51
dr. pal on the rationale for adding cabozantinib to atezolizumab in prostate cancer
-
1:50
dr. gafita on sequencing 177lu-psma-617 in mcrpc
-
1:55
dr. sweeney on chemotherapy versus abiraterone for mcrpc
-
0:54
convincing long-term survival with abiraterone in mcrpc
-
2:05
dr. kohli on sequencing concerns in metastatic hormone-sensitive prostate cancer
-
5:37
oral hormonal agents for metastatc castration-resistant prostate cancer
-
1:12
dr. dreicer on the current role of abiraterone and enzalutamide in prostate cancer